氟哌噻吨美利曲辛片联合奥美拉唑、莫沙必利在慢性胃炎伴反流性食管炎治疗中的应用价值分析

Analysis of the Application Value of Flupenthixone Melitracin Tablets Combined with Omeprazole and Mosapride in the Treatment of Chronic Gastritis with Refl ux Esophagitis

探讨慢性胃炎伴反流性食管炎患者应用氟哌噻吨美利曲辛片联合奥美拉唑、莫沙必利治疗的效果。选取2022年1月—2022年12月武汉体育学院校医院收治的82例慢性胃炎伴反流性食管炎患者为研究对象,采用随机数字表法将其分为对照组和观察组,每组41例。对照组联合应用奥美拉唑、莫沙必利治疗,观察组联合应用氟哌噻吨美利曲辛片、奥美拉唑、莫沙必利治疗。对比两组患者治疗效果。结果显示,观察组患者治疗总有效率高于对照组(P<0.05),胃肠激素和炎症因子水平优于对照组(P<0.05)。研究发现,慢性胃炎伴反流性食管炎患者应用氟哌噻吨美利曲辛片联合奥美拉唑、莫沙必利治疗方案的临床效果显著,可改善患者胃肠激素和炎症因子水平,安全性高,利于患者康复,值得推广应用。

To explore the therapeutic effect of flupenthidomide combined with omeprazole and mosapride on patients with chronic gastritis and reflux esophagitis.82 patients with chronic gastritis and reflux esophagitis admitted to the Wuhan Institute of Physical Education Hospital from January 2022 to December 2022 were selected as the research subjects.They were randomly divided into a control group and an observation group using a random number table method,with 41 patients in each group.The control group was treated with a combination of omeprazole and mosapride,while the observation group was treated with a combination of cefoperazone,omeprazole,and mosapride.Compare the treatment effects of two groups of patients.The results showed that the total effective rate of treatment in the observation group was higher than that in the control group(P<0.05),and the levels of gastrointestinal hormones and inflammatory factors were better than those in the control group(P<0.05).Research has found that the clinical efficacy of the combination therapy offlupenthizumab,omeprazole,and mosapride in patients with chronic gastritis and reflux esophagitis is significant.It can improve the levels of gastrointestinal hormones and inflammatory factors in patients,has high safety,is conducive to patient recovery,and is worthy of promotion and application.